Poland· PL-100512983
Siiltibcy
A medicinal product containing antygeny pochodzące z mycobacterium tuberculosis, registered in Poland by Serum Life Science Europe GmbH.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Antygeny pochodzące z Mycobacterium tuberculosis
- Manufacturer
- Serum Life Science Europe GmbH
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b825687a-7095-43a5-99de-ed499d0db2c1 GET /v1/drugs/b825687a-7095-43a5-99de-ed499d0db2c1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "(0,5 mikrograma + 0,5 mikrograma)/ml \n(rdESAT-6 i rCFP-10)",
"packaging": "Rp ¦ EU/1/24/1882/002 ¦ 160405\n10 fiol. 1 ml\nRp ¦ EU/1/24/1882/001 ¦ 160406\n1 fiol. 1 ml",
"substance": "Antygeny pochodzące z Mycobacterium tuberculosis (0,5 mikrograma + 0,5 mikrograma)/ml \n(rdESAT-6 i rCFP-10)",
"common_name": "Antygeny pochodzące z Mycobacterium tuberculosis",
"pl_product_id": "100512983",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about antygeny pochodzące z mycobacterium tuberculosis.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.